We investigated the effect of an emerging biocompatible ionic liquid, choline dihydrogen phosphate (CDHP), on the stability of high-concentration formulations of Herceptin® (trastuzumab). Our results show that CDHP significantly suppresses unfolding and aggregation of trastuzumab, demonstrating great promise as an additive in the development of stable therapeutic antibody formulations.
M. Reslan, V. Ranganathan, D. R. Macfarlane and V. Kayser, Chem. Commun., 2018, 54, 10622 DOI: 10.1039/C8CC06397D
To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.
If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.
If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.
Read more about how to correctly acknowledge RSC content.
Please wait while we load your content...
